Sartorius Stedim Biotech Reports Strong Half-Year Results for 2025

Aubagne, France | July 22, 2025 — Sartorius Stedim Biotech SA, a leading company in the Life Sciences Tools & Services sector, has released its half-year results for 2025, showcasing a robust financial performance. The company, which specializes in developing and manufacturing laboratory technologies and equipment for industries such as pharmaceuticals, food, public research institutes, and laboratories, reported a sales revenue of 1,490 million euros. This represents a 9.4 percent increase in constant currencies, with a reported growth of 8.5 percent.

The positive financial results align with market expectations, reflecting the company’s strong position in the health care sector. Sartorius Stedim Biotech, listed on the NYSE Euronext Paris, has maintained a market capitalization of 18.78 billion euros as of July 20, 2025. The company’s stock closed at 190.45 EUR, with a 52-week high of 239.8 EUR on January 27, 2025, and a low of 148.75 EUR on April 6, 2025. The price-to-earnings ratio stands at 91.46.

The company’s performance is part of a broader schedule of financial disclosures, as noted in the economic and financial calendar for July 22, 2025. Alongside Sartorius Stedim Biotech, other companies such as Sartorius from Germany, Akzo Nobel from the Netherlands, and several Swiss firms including Julius Bär, Lindt & Sprüngli, and Givaudan, also released their quarterly or half-year results on the same day.

In addition to the financial results, Sartorius Stedim Biotech has provided information on document availability, ensuring transparency and compliance with regulatory requirements. The dissemination of this information was managed by the EQS Group, with the issuer being solely responsible for the content of the announcement.

Overall, Sartorius Stedim Biotech’s strong half-year results underscore its continued growth and resilience in the competitive life sciences industry.